Compare · KDMN vs NEOS
KDMN vs NEOS
Side-by-side comparison of Kadmon Holdings, Inc. (KDMN) and Neos Therapeutics, Inc. (NEOS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KDMN and NEOS operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- KDMN carries a market cap of $1.67B.
- KDMN has more recent analyst coverage (3 ratings vs 0 for NEOS).
- Company
- Kadmon Holdings, Inc.
- Neos Therapeutics, Inc.
- Price
- -
- -
- Market cap
- $1.67B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- 2015
- News (4w)
- 0
- 0
- Recent ratings
- 3
- 0
Kadmon Holdings, Inc.
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York.
Latest KDMN
- Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
- Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
- SEC Form 15-12B filed by Kadmon Holdings, Inc.
- SEC Form EFFECT filed by Kadmon Holdings, Inc.
- SEC Form EFFECT filed by Kadmon Holdings, Inc.
- SEC Form 4: Flowers Cynthia Louise gifted 20,150 shares and returned $103,075 worth of shares to the company (10,850 units at $9.50), closing all direct ownership in the company
- SEC Form 4 filed by Cohen David E
- SEC Form 4 filed by Ryan John L
- SEC Form 4: Waksal Harlan returned $1,690,478 worth of shares to the company (177,945 units at $9.50), closing all direct ownership in the company
- SEC Form 4: Moss Gregory S. returned $167,874 worth of shares to the company (17,671 units at $9.50), closing all direct ownership in the company
Latest NEOS
- FDA Approval for COTEMPLA XR-ODT issued to NEOS THERAPS INC
- FDA Approval for COTEMPLA XR-ODT issued to NEOS THERAPS INC
- SEC Form EFFECT filed by Neos Therapeutics, Inc.
- SEC Form EFFECT filed by Neos Therapeutics, Inc.
- SEC Form EFFECT filed by Neos Therapeutics, Inc.
- SEC Form EFFECT filed by Neos Therapeutics, Inc.
- SEC Form 8-K filed by Neos Therapeutics, Inc.
- SEC Form 425 filed by Neos Therapeutics, Inc.
- SEC Form 4: M John Limongelli disposed to the issuer $0 worth of Common Stock (83,015 units at $0.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Jr. A. James Robinson disposed to the issuer $0 worth of Common Stock (23,453 units at $0.00), decreasing direct ownership by 100% to 0 units